Akademik Veri Yönetim Sistemi
Microchemical Journal, cilt.224, 2026 (SCI-Expanded, Scopus)
Cardiovascular diseases (CVDs) are a primary global health concern and have a significant mortality rate. Early detection of these diseases through cardiovascular biomarkers (such as nTnI and BNP) is crucial in reducing the complications of CVDs. Consequently, the development of advanced diagnostic methods and biosensors has garnered significant attention. The combination of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (CRISPR/Cas) technology, which are known gene editing tools, with biosensors, has been a significant step in creating an innovative technique for detecting molecules and biomarkers, especially cardiovascular biomarkers, for sensitive, accurate, rapid, and early detection of CVDs. Many studies have shown that CRISPR/Cas technology can be integrated with biosensors to detect nucleic acid strands or a variety of protein and lipid biomarkers. This paper aims to investigate the performance of CRISPR/Cas-based biosensors developed for the early detection of cardiovascular diseases. This includes the detection limits and detection ranges obtained by fluorescence, colorimetric, and electrochemical methods in combination with the CRISPR/Cas 12a and CRISPR/Cas 13a systems, for the detection and measurement of various biomarkers of cardiovascular diseases in different clinical samples (plasma and serum) and cell culture. From a prospective perspective, the challenges and limitations of cardiovascular biomarker detection, as well as the potential for clinical use of these CRISPR/Cas-based biosensors, are also discussed.